Athersys, Inc. (NASDAQ:ATHX) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $2.38 and last traded at $2.38, with a volume of 1,515,136 shares traded. The stock had previously closed at $2.22.
Several equities research analysts have issued reports on ATHX shares. Zacks Investment Research cut Athersys from a “buy” rating to a “hold” rating in a research note on Thursday, August 31st. Maxim Group set a $12.00 target price on Athersys and gave the stock a “buy” rating in a research note on Monday, August 7th. Finally, ValuEngine raised Athersys from a “sell” rating to a “hold” rating in a research note on Friday, September 15th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Athersys has a consensus rating of “Buy” and a consensus price target of $7.17.
The stock’s market capitalization is $290.47 million. The firm’s 50 day moving average price is $1.77 and its 200 day moving average price is $1.54.
Athersys (NASDAQ:ATHX) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). Athersys had a negative return on equity of 121.47% and a negative net margin of 729.07%. The firm had revenue of $0.67 million during the quarter, compared to the consensus estimate of $0.96 million. During the same period in the prior year, the firm earned ($0.08) EPS. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. Equities analysts predict that Athersys, Inc. will post ($0.24) EPS for the current fiscal year.
In related news, EVP John J. Harrington sold 15,000 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $2.17, for a total value of $32,550.00. Following the completion of the sale, the executive vice president now directly owns 679,416 shares in the company, valued at approximately $1,474,332.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 9.40% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its holdings in Athersys by 4.8% in the 1st quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 2,800 shares in the last quarter. NEXT Financial Group Inc increased its holdings in Athersys by 3.2% in the 2nd quarter. NEXT Financial Group Inc now owns 97,950 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 3,000 shares in the last quarter. Bank of America Corp DE increased its holdings in Athersys by 17.2% in the 1st quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 9,019 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Athersys by 7.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 284,540 shares of the biopharmaceutical company’s stock valued at $430,000 after purchasing an additional 19,375 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Athersys by 34.2% in the 2nd quarter. Rhumbline Advisers now owns 110,064 shares of the biopharmaceutical company’s stock valued at $166,000 after purchasing an additional 28,030 shares in the last quarter. Hedge funds and other institutional investors own 19.08% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Athersys, Inc. (ATHX) Hits New 52-Week High at $2.38” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/20/athersys-inc-athx-hits-new-52-week-high-at-2-38.html.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.